3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
3
Neoplasm Metastasis
2
Kidney Neoplasms
2
Urogenital Neoplasms
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
PRETEXT I Hepatoblastoma
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Breast Neoplasms
1
Interventions
padeliporfin
3
Mitomycin
2
valrubicin
1
temsirolimus
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
enfortumab vedotin
1
abiraterone
1
abemaciclib
1
Tadalafil
1
Standard of Care
1
Radiation Dose Hypofractionation
1
Prednisone
1
Prednisolone
1
Phosphodiesterase 5 Inhibitors
1
Gemcitabine
1
Fluorouracil
1
Drug Therapy
1
Cisplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Urogenital Neoplasms
×
temsirolimus
×
Clear all
NCT00631371
2016-04-27
INTORACT
Pfizer
Phase 3
Completed
791 enrolled
11 charts